Truist lowered the firm’s price target on Intellia Therapeutics (NTLA) to $14 from $25 but keeps a Buy rating on the shares. Despite the unfortunate patient death from the MAGNITUDE trial, there is still a path forward for nex-Z given the “complex medical history” of this greater than 80 year old receiving the drug, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat
- Intellia Therapeutics price target lowered to $15 from $18 at H.C. Wainwright
- Intellia Therapeutics presents Phase 1/2 data on lonvo-z
- Intellia Therapeutics’ Earnings Call: Progress Amid Challenges
- Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed